DK3400290T5 - Onkolytisk virusstamme - Google Patents

Onkolytisk virusstamme Download PDF

Info

Publication number
DK3400290T5
DK3400290T5 DK17700384.5T DK17700384T DK3400290T5 DK 3400290 T5 DK3400290 T5 DK 3400290T5 DK 17700384 T DK17700384 T DK 17700384T DK 3400290 T5 DK3400290 T5 DK 3400290T5
Authority
DK
Denmark
Prior art keywords
virus strain
oncolytic virus
oncolytic
strain
virus
Prior art date
Application number
DK17700384.5T
Other languages
Danish (da)
English (en)
Other versions
DK3400290T3 (da
Inventor
Robert Coffin
Original Assignee
Replimune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57796748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3400290(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1600381.6A external-priority patent/GB201600381D0/en
Priority claimed from GBGB1600382.4A external-priority patent/GB201600382D0/en
Priority claimed from GBGB1600380.8A external-priority patent/GB201600380D0/en
Application filed by Replimune Ltd filed Critical Replimune Ltd
Publication of DK3400290T3 publication Critical patent/DK3400290T3/da
Application granted granted Critical
Publication of DK3400290T5 publication Critical patent/DK3400290T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK17700384.5T 2016-01-08 2017-01-09 Onkolytisk virusstamme DK3400290T5 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1600381.6A GB201600381D0 (en) 2016-01-08 2016-01-08 Virus strain
GBGB1600382.4A GB201600382D0 (en) 2016-01-08 2016-01-08 Engineered virus
GBGB1600380.8A GB201600380D0 (en) 2016-01-08 2016-01-08 Modified virus
PCT/GB2017/050037 WO2017118865A1 (en) 2016-01-08 2017-01-09 Oncolytic virus strain

Publications (2)

Publication Number Publication Date
DK3400290T3 DK3400290T3 (da) 2023-05-01
DK3400290T5 true DK3400290T5 (da) 2024-09-23

Family

ID=57796748

Family Applications (4)

Application Number Title Priority Date Filing Date
DK17700384.5T DK3400290T5 (da) 2016-01-08 2017-01-09 Onkolytisk virusstamme
DK17701910.6T DK3400293T4 (da) 2016-01-08 2017-01-09 Modificeret onkolytisk virus
DK20197725.3T DK3805376T3 (da) 2016-01-08 2017-01-09 Modificeret virus
DK17700385.2T DK3400291T4 (da) 2016-01-08 2017-01-09 Manipuleret virus

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK17701910.6T DK3400293T4 (da) 2016-01-08 2017-01-09 Modificeret onkolytisk virus
DK20197725.3T DK3805376T3 (da) 2016-01-08 2017-01-09 Modificeret virus
DK17700385.2T DK3400291T4 (da) 2016-01-08 2017-01-09 Manipuleret virus

Country Status (13)

Country Link
US (13) US10570377B2 (enExample)
EP (8) EP3400290B1 (enExample)
JP (8) JP6959258B2 (enExample)
KR (2) KR20250026348A (enExample)
CN (3) CN109153977B (enExample)
AU (2) AU2017205216B2 (enExample)
CA (3) CA3011004A1 (enExample)
DK (4) DK3400290T5 (enExample)
ES (4) ES2943150T3 (enExample)
IL (2) IL260480B (enExample)
MX (1) MX2018008413A (enExample)
SG (2) SG10202108724YA (enExample)
WO (4) WO2017118864A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100802403B1 (ko) * 2000-01-21 2008-02-13 바이오벡스 리미티드 바이러스 주
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
EP2158668A4 (en) 2007-05-31 2017-07-19 Krishnan Ramu Switched reluctance machines with minimum stator core
MD4655C1 (ro) 2013-03-14 2020-06-30 Icahn School Of Medicine At Mount Sinai Virusurile bolii de Newcastle şi utilizarea acestora
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
HK1248115A1 (zh) 2015-07-16 2018-10-12 Bioxcel Therapeutics, Inc. 一种使用免疫调节治疗癌症的新颖方法
DK3400290T5 (da) 2016-01-08 2024-09-23 Replimune Ltd Onkolytisk virusstamme
EP4089166A1 (en) 2016-01-27 2022-11-16 Oncorus, Inc. Oncolytic viral vectors and uses thereof
RU2769314C1 (ru) 2016-03-16 2022-03-30 Амаль Терапьютикс Са Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине
EP3380621A4 (en) * 2016-04-22 2019-05-08 Immvira Co., Limited CONSTRUCTION OF THE VECTOR OF OBLIGATES ONCOLYTIC HERPES SIMPLEX VIRUSES (OHSV) AND CANCER THERAPY CONSTRUCTIONS
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US10888594B2 (en) 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
EP3478321A4 (en) * 2016-06-30 2020-04-22 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
HUE067838T2 (hu) 2016-09-21 2024-11-28 Amal Therapeutics Sa Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
EP4063859A1 (en) 2017-04-28 2022-09-28 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
KR20200042904A (ko) 2017-07-26 2020-04-24 온코루스, 인크. 종양용해성 바이러스 벡터 및 그의 용도
CA3071376A1 (en) 2017-08-03 2019-02-07 Amgen Inc. Interleukin-21 muteins and methods of treatment
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
CN109554353B (zh) * 2017-09-26 2021-08-06 杭州康万达医药科技有限公司 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
JP7277926B2 (ja) * 2017-11-08 2023-05-19 国立大学法人 鹿児島大学 安全を確保しながら転移性がんまで効果的に治療可能な、搭載する免疫誘導遺伝子の最適発現レベルを与える発現制御システムを有する腫瘍溶解性ウイルス（腫瘍溶解性免疫治療）
MX2020004914A (es) * 2017-11-13 2020-10-28 Bioxcel Therapeutics Inc Metodos y composiciones para tratar el cancer mediante la modificacion de multiples brazos del sistema inmunitario.
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
AU2019207895A1 (en) 2018-01-12 2020-06-18 Amgen Inc. Anti-PD-1 antibodies and methods of treatment
EP3743095A1 (en) * 2018-01-26 2020-12-02 Celldex Therapeutics, Inc. Methods of treating cancer with dendritic cell mobilizing agents
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
CN108635380A (zh) * 2018-04-13 2018-10-12 北京唯源立康生物科技有限公司 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用
US20210252135A1 (en) * 2018-06-21 2021-08-19 Replimune Limited Treatment using oncolytic virus
JP2021529531A (ja) * 2018-06-29 2021-11-04 クリスタル バイオテック インコーポレイテッド 抗体送達のための組成物及び方法
CN109161561A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
CN119955743A (zh) * 2018-09-10 2025-05-09 上海锦斯生物技术有限公司 修饰的溶瘤病毒、其组合物和用途
PH12021550661A1 (en) * 2018-09-26 2022-03-21 Astellas Pharma Inc Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
MX2021007639A (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas.
CN111606999B (zh) * 2019-02-26 2022-09-06 南京惟亚德生物医药有限公司 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用
KR20210135532A (ko) * 2019-03-05 2021-11-15 암젠 인크 암 치료를 위한 종양 용해 바이러스의 용도
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
CN110054678B (zh) * 2019-05-16 2023-04-18 中国医学科学院血液病医院（血液学研究所） 一种膜结合型mFLT3LG蛋白及其应用
CN110218707B (zh) * 2019-05-29 2021-10-22 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
JPWO2021024897A1 (enExample) * 2019-08-05 2021-02-11
JP7699122B2 (ja) * 2019-11-06 2025-06-26 メムゲン，インコーポレイテッド 複製促進腫瘍溶解性アデノウイルス
CN110982795B (zh) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 一种单纯疱疹病毒及其用途
CN110982794B (zh) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 一种修饰的单纯疱疹病毒
CN113046331B (zh) * 2020-03-05 2022-09-13 北京唯源立康生物科技股份有限公司 非复制性重组疱疹病毒及其用途
JPWO2021193081A1 (enExample) * 2020-03-23 2021-09-30
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
CN112941039A (zh) * 2021-02-01 2021-06-11 南京大学 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用
DE102022104146A1 (de) 2021-03-19 2022-09-22 Yamada Manufacturing Co., Ltd. Lenkvorrichtung
CA3215085A1 (en) * 2021-04-08 2022-10-13 Immvira Biopharmaceuticals Co., Limited Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen
US20240245739A1 (en) * 2021-05-18 2024-07-25 The Penn State Research Foundation Oncolytic virus based cancer therapy
CN113583979B (zh) * 2021-08-03 2022-11-22 杭州荣谷生物科技有限公司 一种重组溶瘤痘苗病毒、制备方法及其用途
CN118510619A (zh) 2022-01-11 2024-08-16 三菱综合材料株式会社 表面包覆切削工具
WO2024055022A2 (en) * 2022-09-08 2024-03-14 Virogin Biotech Canada Ltd Oncolytic virus expressing an immune cell engager for tumor targeting
WO2025248110A1 (en) * 2024-05-31 2025-12-04 Replimune Limited An oncolytic herpes simplex virus (hsv) and an anti-pd-1 antibody for use in treating braf mutant melanoma

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US6040169A (en) 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
EP0675961B1 (en) 1992-03-31 2002-11-27 Arch Development Corporation Treatment of tumorigenic disease with a modified HSV
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
WO1997012623A1 (en) 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
MXPA02004736A (es) 1999-11-12 2003-01-28 Oncolytics Biotech Inc Virus para el tratamiento de trastornos proliferativos celulares.
KR100802403B1 (ko) 2000-01-21 2008-02-13 바이오벡스 리미티드 바이러스 주
JP4212897B2 (ja) 2001-03-27 2009-01-21 具紀 藤堂 ウイルスおよび治療法におけるそれらの使用
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
WO2006002394A2 (en) * 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
BRPI0515735A2 (pt) 2004-11-04 2011-10-11 Pfizer Prod Inc tratamento de combinação de anticorpo de ctla4 e inibidor de aromatase para cáncer de mama, suas composições farmacêuticas e respectivos usos
US9866961B2 (en) 2004-12-01 2018-01-09 Todd Beauchamp Multi-channel loudspeaker enclosure with laterally projecting wings and method for orienting and driving multiple loudspeakers
DK1865986T3 (en) 2005-03-08 2016-04-11 Pfizer Prod Inc The anti-CTLA-4 antibody compositions
EP2650020B1 (en) 2005-05-06 2016-08-24 Providence Health & Services - Oregon Trimeric OX40-immunoglobulin fusion protein and methods of use
US8986672B2 (en) 2005-06-23 2015-03-24 The University Of Houston Use of mutant Herpes Simplex Virus-2 for cancer therapy
GB0522476D0 (en) * 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
US8313896B2 (en) * 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
WO2009148488A2 (en) 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
JP2012504959A (ja) 2008-10-08 2012-03-01 イントレキソン コーポレーション 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
AU2010321773A1 (en) 2009-11-20 2012-06-14 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
WO2011118866A1 (ko) 2010-03-26 2011-09-29 연세대학교 산학협력단 네트워크를 통한 심사요청 방법
EP2619312A1 (en) * 2010-09-24 2013-07-31 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
RS58146B1 (sr) * 2011-09-08 2019-02-28 Univ New York Onkolitički herpes simpleks virus i njegova terapeutska upotreba
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
EP2806883B1 (en) 2012-01-25 2019-04-24 DNAtrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
EP2879498A4 (en) 2012-07-30 2016-03-30 Alex Wah Hin Yeung BY TREATMENT OF AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE TEST MODULE DEVELOPED TUMOR SPECIFIC LIVING AND IN VIVO CANCER VACCINE SYSTEM
AU2013308595C1 (en) * 2012-08-30 2019-01-17 Amgen Inc. A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
WO2014066532A1 (en) 2012-10-23 2014-05-01 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
CN104994879A (zh) 2013-02-22 2015-10-21 霍夫曼-拉罗奇有限公司 治疗癌症和预防药物抗性的方法
MD4655C1 (ro) 2013-03-14 2020-06-30 Icahn School Of Medicine At Mount Sinai Virusurile bolii de Newcastle şi utilizarea acestora
TR201902073T4 (tr) 2013-09-03 2019-03-21 Medimmune Ltd Bir atenüe Newcastle hastalığı virüsü sağlayan bileşimler ve neoplaziyi tedavi etmek için kullanım yöntemleri.
TR201802728T4 (tr) 2013-10-25 2018-03-21 Psioxus Therapeutics Ltd Heterolog genlerle donatılmış onkolitik adenovirüsler.
JP6588024B2 (ja) 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性ｈｓｖベクター
CA2931322A1 (en) 2013-11-22 2015-05-28 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
US10933106B2 (en) 2014-02-25 2021-03-02 Deutsches Krebsforschungszentrum RNA viruses for immunovirotherapy
MA39818A (fr) * 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
JP6895374B2 (ja) 2014-07-16 2021-06-30 トランジェーヌＴｒａｎｓｇｅｎｅ 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
JP6843736B2 (ja) 2014-07-16 2021-03-17 トランジェーヌＴｒａｎｓｇｅｎｅ 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ
US20160040186A1 (en) 2014-08-07 2016-02-11 Xiaoyun Liu Dna construct and method for transgene expression
GB201419579D0 (en) 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
US10525557B2 (en) 2015-01-23 2020-01-07 Dreamwell, Ltd. Automated mattress manufacturing process and apparatus
DK3400290T5 (da) 2016-01-08 2024-09-23 Replimune Ltd Onkolytisk virusstamme
EP3380621A4 (en) 2016-04-22 2019-05-08 Immvira Co., Limited CONSTRUCTION OF THE VECTOR OF OBLIGATES ONCOLYTIC HERPES SIMPLEX VIRUSES (OHSV) AND CANCER THERAPY CONSTRUCTIONS
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
US12029647B2 (en) * 2017-03-07 2024-07-09 4C Medical Technologies, Inc. Systems, methods and devices for prosthetic heart valve with single valve leaflet
US20210252135A1 (en) 2018-06-21 2021-08-19 Replimune Limited Treatment using oncolytic virus
TW202039851A (zh) 2018-12-21 2020-11-01 美商特斯通生物技術公司 經修飾正痘病毒載體

Also Published As

Publication number Publication date
AU2017205216A1 (en) 2018-08-09
DK3400291T3 (da) 2020-11-30
MX2018008413A (es) 2019-02-20
US20230212531A1 (en) 2023-07-06
DK3400291T4 (da) 2024-04-02
CN109153977B (zh) 2022-11-01
WO2017118864A1 (en) 2017-07-13
EP3805376B1 (en) 2025-08-06
EP3400291A1 (en) 2018-11-14
AU2022279486A1 (en) 2023-02-02
EP3400291B2 (en) 2024-02-28
JP2023113885A (ja) 2023-08-16
US20240018488A1 (en) 2024-01-18
EP3400293B1 (en) 2020-09-16
US20190022157A1 (en) 2019-01-24
SG11201805835WA (en) 2018-08-30
EP3400291B1 (en) 2020-11-04
IL282985B (en) 2022-04-01
CN109415703A (zh) 2019-03-01
US12397053B2 (en) 2025-08-26
AU2022279486B2 (en) 2025-07-31
US20230203453A1 (en) 2023-06-29
DK3805376T3 (da) 2025-09-29
HK1257480A1 (en) 2019-10-18
US12458696B2 (en) 2025-11-04
US20190032024A1 (en) 2019-01-31
EP4219696A2 (en) 2023-08-02
US10570377B2 (en) 2020-02-25
CN109415703B (zh) 2024-08-30
ES2943150T3 (es) 2023-06-09
EP3400293B2 (en) 2023-07-12
JP2022002531A (ja) 2022-01-11
US20240301365A1 (en) 2024-09-12
EP3400292B1 (en) 2020-08-26
KR20180103956A (ko) 2018-09-19
US12024724B2 (en) 2024-07-02
DK3400293T3 (da) 2020-10-19
EP3400293A1 (en) 2018-11-14
JP2024153748A (ja) 2024-10-29
CA3011009A1 (en) 2017-07-13
US12465639B2 (en) 2025-11-11
US11473063B2 (en) 2022-10-18
JP2025163138A (ja) 2025-10-28
HK1257074A1 (en) 2019-10-11
IL260480B (en) 2021-05-31
US12049647B2 (en) 2024-07-30
CN109312309A (zh) 2019-02-05
ES2841300T5 (es) 2024-08-06
EP3400292A1 (en) 2018-11-14
WO2017118865A1 (en) 2017-07-13
JP2022078225A (ja) 2022-05-24
US20190015466A1 (en) 2019-01-17
CA3011004A1 (en) 2017-07-13
US20200199542A1 (en) 2020-06-25
JP7038664B2 (ja) 2022-03-18
DK3400290T3 (da) 2023-05-01
AU2017205216B2 (en) 2022-11-24
ES2831080T3 (es) 2021-06-07
EP3778881A1 (en) 2021-02-17
EP3805376A1 (en) 2021-04-14
DK3400293T4 (da) 2023-08-28
US20230130992A1 (en) 2023-04-27
EP4219696A3 (en) 2023-09-27
JP7038065B2 (ja) 2022-03-17
ES2841300T3 (es) 2021-07-08
US10612005B2 (en) 2020-04-07
US20190040366A1 (en) 2019-02-07
EP3400290A1 (en) 2018-11-14
JP2019501670A (ja) 2019-01-24
US20210254019A1 (en) 2021-08-19
CA3010987A1 (en) 2017-07-13
KR20250026348A (ko) 2025-02-25
ES2831080T5 (es) 2023-10-30
JP6959258B2 (ja) 2021-11-02
EP3400290B1 (en) 2023-04-05
ES3041885T3 (en) 2025-11-17
KR102762431B1 (ko) 2025-02-03
CN109312309B (zh) 2024-04-02
IL282985A (en) 2021-06-30
US10626377B2 (en) 2020-04-21
US20250352646A1 (en) 2025-11-20
JP2019501671A (ja) 2019-01-24
BR112018013930A2 (pt) 2018-12-11
JP2019500909A (ja) 2019-01-17
US10947513B2 (en) 2021-03-16
WO2017118866A1 (en) 2017-07-13
JP7295192B2 (ja) 2023-06-20
WO2017118867A1 (en) 2017-07-13
SG10202108724YA (en) 2021-09-29
US11427810B2 (en) 2022-08-30
CN109153977A (zh) 2019-01-04
HK1257224A1 (en) 2019-10-18
EP4628577A2 (en) 2025-10-08
US20200208122A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
IL282985B (en) Modified oncolytic viurs
HUE062816T2 (hu) Onkolitikus vakciniavírus
DK3565568T3 (da) Ændret virus
HUE054967T2 (hu) Új genetikailag módosított Vaccinia vírus
DK3393510T3 (da) Zikavirusvaccine
HUE042693T2 (hu) Kapszid
DK3172319T3 (da) Coronavirus
DK3108000T3 (da) Adeno-associeret virusvektor
DK3642340T3 (da) Modificeret L-asparaginase
EP3388526A4 (en) MICRO BACTERIA
DK3130392T3 (da) Virusfjernelsesmembran
EP3521414A4 (en) XYLARIA GRAMMICA
MA45305A (fr) Suspension améliorée
EP3486310A4 (en) Leuconostoc MESENTEROIDE
EP3625349A4 (en) MODIFIED VIRUSES
EP3384016A4 (en) MANIPULATED PHAGEMIDES
EP3511016A4 (en) Immunostimulant
EP3500280A4 (en) VIRUS VACCINES
DK3263590T3 (da) Fiskevirus
IL247535B (en) Poxviral oncolytic vectors
FI20165334A7 (fi) Kirves
EP3624825A4 (en) RECOMBINANT ONCOLYTIC VIRUS
DK3371324T3 (da) Virusbiomarkører og anvendelser deraf
DE112016005089A5 (de) Zyklonsystem
EP3476930A4 (en) Pseudozyma